Table 4.
Joint effects of smoking status with miR-29b and DNMT3B mRNA in lung cancer development.
| Cases | Controls | |||
|---|---|---|---|---|
| Variables | n = 132 | n = 132 | OR (95% CI) | p-Value a |
| Smoking status/miR-29b | ||||
| Smokers/Low | 45 (34.1%) | 33 (25.0%) | 3.95 (2.37–6.59) | <0.001 |
| Smokers/High | 28 (21.2%) | 10 (7.6%) | 6.09 (3.35–11.07) | < 0.001 |
| Non-smokers/Low | 50 (37.9%) | 33 (25.0%) | 3.27 (2.06–5.19) | <0.001 |
| Non-smokers/High | 9 (6.8%) | 56 (42.4%) | 1.00 (reference) | |
| Test for interaction | χ2 = 27.73 (1 df); p < 0.001 | |||
| Smoking status/DNMT3B mRNA | ||||
| Smokers/High | 61 (46.2%) | 22 (16.7%) | 2.96 (1.94–4.50) | <0.001 |
| Smokers/Low | 12 (9.1%) | 21 (15.9%) | 1.17 (0.72–1.89) | 0.53 |
| Non-smokers/High | 27 (20.5%) | 44 (33.3%) | 0.94 (0.65–1.37) | 0.77 |
| Non-smokers/Low | 32 (24.2%) | 45 (34.1%) | 1.00 (reference) | |
| Test for interaction | χ2 = 10.89 (1 df); p = 0.001 | |||
| Smoking status/miR-29b/DNMT3B mRNA | ||||
| Smokers/Low/High | 36 (27.3%) | 16 (12.1%) | 5.12 (2.64–9.91) | <0.001 |
| Smokers/Low/Low | 9 (6.8%) | 17 (12.9%) | 2.04 (1.00–4.15) | 0.054 |
| Smokers/High/High | 25 (18.9%) | 6 (4.6%) | 6.88 (3.27–14.46) | <0.001 |
| Smokers/High/Low | 3 (2.3%) | 4 (3.0%) | 3.38 (1.26–9.08) | 0.02 |
| Non-smokers/Low/High | 22 (16.7%) | 13 (9.9%) | 3.18 (1.65–6.15) | 0.001 |
| Non-smokers/Low/Low | 28 (21.2%) | 20 (15.2%) | 2.79 (1.49–5.21) | 0.002 |
| Non-smokers/High/High | 5 (3.8%) | 31 (23.4%) | 0.83 (0.38–1.83) | 0.65 |
| Non-smokers/High/Low | 4 (3.0%) | 25 (18.9%) | 1.00 (reference) | |
| Test for interaction | χ2 = 34.26 (3 df); p < 0.001 | |||
| p for trend | <0.001 | |||
OR, odds ratio; CI, confidence interval. a Data were matched by age and gender, calculated by log-linear regression, adjusted for green tea consumption, exposure to cooking fumes, and family history of lung cancer.